Boulegeris Investments Inc. Has $4.26 Million Holdings in Allergan plc (AGN)
Boulegeris Investments Inc. lessened its holdings in Allergan plc (NYSE:AGN) by 23.6% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 26,014 shares of the company’s stock after selling 8,052 shares during the quarter. Allergan comprises approximately 2.2% of Boulegeris Investments Inc.’s investment portfolio, making the stock its 8th largest holding. Boulegeris Investments Inc.’s holdings in Allergan were worth $4,255,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of AGN. Ballentine Partners LLC lifted its position in shares of Allergan by 12.5% during the 3rd quarter. Ballentine Partners LLC now owns 2,664 shares of the company’s stock worth $546,000 after purchasing an additional 295 shares during the last quarter. Windward Capital Management Co. CA lifted its position in shares of Allergan by 9.4% during the 4th quarter. Windward Capital Management Co. CA now owns 3,475 shares of the company’s stock worth $568,000 after purchasing an additional 298 shares during the last quarter. First Capital Advisors Group LLC. lifted its position in shares of Allergan by 23.3% during the 3rd quarter. First Capital Advisors Group LLC. now owns 1,614 shares of the company’s stock worth $331,000 after purchasing an additional 305 shares during the last quarter. Graybill Bartz & Assoc Ltd. lifted its position in shares of Allergan by 1.7% during the 4th quarter. Graybill Bartz & Assoc Ltd. now owns 18,456 shares of the company’s stock worth $3,019,000 after purchasing an additional 305 shares during the last quarter. Finally, Community Trust & Investment Co. lifted its position in shares of Allergan by 0.6% during the 3rd quarter. Community Trust & Investment Co. now owns 50,638 shares of the company’s stock worth $10,378,000 after purchasing an additional 316 shares during the last quarter. 79.66% of the stock is owned by institutional investors.
Shares of Allergan plc (AGN) opened at $144.02 on Friday. Allergan plc has a 1 year low of $143.10 and a 1 year high of $256.80. The firm has a market cap of $51,620.00, a price-to-earnings ratio of -12.01, a P/E/G ratio of 1.05 and a beta of 1.29. The company has a quick ratio of 1.06, a current ratio of 1.16 and a debt-to-equity ratio of 0.38.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 28th. Shareholders of record on Wednesday, February 28th will be paid a $0.72 dividend. The ex-dividend date is Tuesday, February 27th. This is a positive change from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 dividend on an annualized basis and a yield of 2.00%. Allergan’s payout ratio is currently -24.02%.
AGN has been the subject of several recent analyst reports. Argus cut shares of Allergan from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $256.80 to $160.07 in a research report on Thursday, December 7th. Barclays raised shares of Allergan from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $220.00 to $230.00 in a research report on Monday, January 29th. They noted that the move was a valuation call. Deutsche Bank reaffirmed a “buy” rating and set a $215.00 price objective on shares of Allergan in a research report on Tuesday, January 9th. Zacks Investment Research cut shares of Allergan from a “hold” rating to a “sell” rating in a research report on Tuesday, January 2nd. Finally, Vetr cut shares of Allergan from a “strong-buy” rating to a “buy” rating and set a $187.73 price objective for the company. in a research report on Wednesday, December 6th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and fifteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $225.03.
In other Allergan news, insider William Meury sold 58,879 shares of Allergan stock in a transaction on Wednesday, February 14th. The shares were sold at an average price of $160.62, for a total value of $9,457,144.98. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Chris W. Bodine acquired 3,030 shares of the company’s stock in a transaction on Thursday, December 7th. The stock was acquired at an average price of $164.77 per share, for a total transaction of $499,253.10. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 19,630 shares of company stock worth $3,211,937. 0.36% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: This piece was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was stolen and reposted in violation of US and international copyright and trademark law. The original version of this piece can be accessed at https://www.watchlistnews.com/boulegeris-investments-inc-has-4-26-million-holdings-in-allergan-plc-agn/1906314.html.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.